• 1
    Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009;50:204-210.
  • 2
    Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-889.
  • 3
    Musso G, Gambino R, Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 2010;61:375-392.
  • 4
    Arrese M, Karpen SJ. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 2010;87:473-478.
  • 5
    Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012;13:213-224.
  • 6
    Beltowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther 2008;26:297-316.
  • 7
    Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002;277:11019-11025.
  • 8
    Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182-34190.
  • 9
    Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond implications for drug design. Prog Lipid Res 2010;49:343-352.
  • 10
    Hummasti S, Laffitte BA, Watson MA, Galardi C, Chao LC, Ramamurthy L, et al. Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J Lipid Res 2004;45:616-625.
  • 11
    LaFave LT, Augustin LB, Mariash CN. S14: insights from knockout mice. Endocrinology 2006;147:4044-4047.
  • 12
    Breuker C, Moreau A, Lakhal L, Tamasi V, Parmentier Y, Meyer U, et al. Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). Endocrinology 2010;151:1653-1661.
  • 13
    Zilz ND, Murray MB, Towle HC. Identification of multiple thyroid hormone response elements located far upstream from the rat S14 promoter. J Biol Chem 1990;265:8136-8143.
  • 14
    Zhu Q, Anderson GW, Mucha GT, Parks EJ, Metkowski JK, Mariash CN. The Spot 14 protein is required for de novo lipid synthesis in the lactating mammary gland. Endocrinology 2005;146:3343-3350.
  • 15
    Zhu Q, Mariash A, Margosian MR, Gopinath S, Fareed MT, Anderson GW, Mariash CN. Spot 14 gene deletion increases hepatic de novo lipogenesis. Endocrinology 2001;142:4363-4370.
  • 16
    Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 2002;277:9520-9528.
  • 17
    Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 2001;107:565-573.
  • 18
    Li J, Chi Y, Wang C, Wu J, Yang H, Zhang D, et al. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway. Hepatology 2011;53:1906-1916.
  • 19
    Wang Q, Jiang L, Wang J, Li S, Yu Y, You J, et al. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology 2009;49:1166-1175.
  • 20
    Forman BM, Ruan B, Chen J, Schroepfer GJ, Jr., Evans RM. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci U S A 1997;94:10588-10593.
  • 21
    Wang R, Kong X, Cui A, Liu X, Xiang R, Yang Y, et al. Sterol-regulatory-element-binding protein 1c mediates the effect of insulin on the expression of Cidea in mouse hepatocytes. Biochem J 2010;430:245-254.
  • 22
    Jump DB, Thelen AP, Mater MK. Functional interaction between sterol regulatory element-binding protein-1c, nuclear factor Y, and 3,5,3’-triiodothyronine nuclear receptors. J Biol Chem 2001;276:34419-34427.
  • 23
    Moreau A, Teruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, et al. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009;49:2068-2079.
  • 24
    Mitro N, Vargas L, Romeo R, Koder A, Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 2007;581:1721-1726.
  • 25
    Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF, Burris TP. T0901317 is a dual LXR/FXR agonist. Mol Genet Metab 2004;83:184-187.
  • 26
    Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000;14:2819-2830.
  • 27
    Martel PM, Bingham CM, McGraw CJ, Baker CL, Morganelli PM, Meng ML, et al. S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth. Exp Cell Res 2006;312:278-288.
  • 28
    Chou WY, Cheng YS, Ho CL, Liu ST, Liu PY, Kuo CC, et al. Human spot 14 protein interacts physically and functionally with the thyroid receptor. Biochem Biophys Res Commun 2007;357:133-138.
  • 29
    Chou WY, Ho CL, Tseng ML, Liu ST, Yen LC, Huang SM. Human Spot 14 protein is a p53-dependent transcriptional coactivator via the recruitment of thyroid receptor and Zac1. Int J Biochem Cell Biol 2008;40:1826-1834.
  • 30
    Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002;99:7604-7609.
  • 31
    Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-219.
  • 32
    Blaschke F, Leppanen O, Takata Y, Caglayan E, Liu J, Fishbein MC, et al. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 2004;95:e110-e123.
  • 33
    Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 2003;100:5419-5424.
  • 34
    Wu J, Zhang Y, Wang N, Davis L, Yang G, Wang X, et al. Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol 2004;287:F886-F895.
  • 35
    Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008;134:556-567.
  • 36
    Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, et al. LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 2011;121:431-441.
  • 37
    Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, et al. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res 2010;51:900-906.
  • 38
    Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos 2001;29:1325-1331.
  • 39
    Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804.
  • 40
    Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbarrini A, Gasbarrini G. Fatty liver and drugs. Eur Rev Med Pharmacol Sci 2005;9:261-263.